Evolent Health Inc (NYSE:EVH) – Equities research analysts at William Blair lifted their FY2017 earnings per share estimates for Evolent Health in a research report issued on Wednesday, Zacks Investment Research reports. William Blair analyst R. Daniels now expects that the technology company will post earnings per share of ($0.35) for the year, up from their prior estimate of ($0.58).
EVH has been the topic of a number of other reports. Leerink Swann set a $25.00 target price on shares of Evolent Health and gave the stock a “buy” rating in a research report on Saturday, November 18th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $30.00 target price on shares of Evolent Health in a research report on Thursday, November 2nd. SunTrust Banks reaffirmed a “buy” rating and set a $30.00 target price on shares of Evolent Health in a research report on Friday, November 3rd. Citigroup started coverage on shares of Evolent Health in a research report on Thursday, January 4th. They set a “buy” rating on the stock. Finally, Goldman Sachs Group lowered shares of Evolent Health from a “conviction-buy” rating to a “buy” rating in a research report on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $28.00.
Shares of Evolent Health (NYSE EVH) traded down $0.07 during trading hours on Monday, hitting $14.10. 595,456 shares of the stock were exchanged, compared to its average volume of 1,070,000. The stock has a market capitalization of $1,090.00 and a price-to-earnings ratio of -12.37. Evolent Health has a fifty-two week low of $10.30 and a fifty-two week high of $27.50. The company has a current ratio of 3.34, a quick ratio of 3.34 and a debt-to-equity ratio of 0.11.
Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Thursday, November 2nd. The technology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.04. The business had revenue of $107.90 million during the quarter, compared to the consensus estimate of $104.49 million. Evolent Health had a negative net margin of 15.86% and a negative return on equity of 5.05%. The firm’s quarterly revenue was up 79.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.26) earnings per share.
A number of hedge funds have recently modified their holdings of EVH. ETF Managers Group LLC purchased a new position in Evolent Health during the second quarter valued at approximately $102,000. BNP Paribas Arbitrage SA increased its holdings in Evolent Health by 815.4% during the second quarter. BNP Paribas Arbitrage SA now owns 4,751 shares of the technology company’s stock valued at $120,000 after buying an additional 4,232 shares during the period. SG Americas Securities LLC purchased a new position in Evolent Health during the third quarter valued at approximately $156,000. Fox Run Management L.L.C. purchased a new position in Evolent Health during the fourth quarter valued at approximately $175,000. Finally, IPG Investment Advisors LLC purchased a new position in Evolent Health during the third quarter valued at approximately $195,000. 95.57% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Analysts Offer Predictions for Evolent Health Inc’s FY2017 Earnings (EVH)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/01/31/evolent-health-inc-evh-to-post-fy2017-earnings-of-0-35-per-share-william-blair-forecasts.html.
About Evolent Health
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Get a free copy of the Zacks research report on Evolent Health (EVH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.